Is the red cell distribution width strong predictor for treatment response in primary glomerulonephritides?

Abstract

Background: Novel biomarkers are needed to predict the response to treatment in patients with nephrotic syndrome (NS) due to primary glomerulonephritides (PGN). We aimed to test the predictive value of red blood cell distribution width (RDW) for estimation of response to therapy in adult patients with NS. Study design, setting & participants, and intervention: We performed a prospective study including 176 patients with NS due to PGN. Patients were divided into three groups according to their response to the treatment. Group 1 was composed of patients with complete remission whereas group 2 was composed of patients with partial remission and group 3 was composed of patients who were resistant to the treatment. Results: The highest baseline mean RDW value was found in group 3 patients (17.8 ± 1.8) whereas the lowest in group 1 (13.4 ± 0.7) before treatment (p50.05). We found a significant decrease in RDW value after an effective treatment in groups 1 and group 2 (p50.05). However, there was no significant change in RDW values after treatment in group 3 (p40.05). Most of the patient with complete remission had base-line RDW level 14% (n ¼ 45, 90%) (p50.001, Kendal Tau: À0.86), and most of the patients who were resistant to the treatment had base-line RDW level p415% (n ¼ 68, 86.1%) (p50.001, Kendal Tau: À0.87). Conclusion: Our results suggest that pre-treatment RDW value is a promising novel biomarker for predicting response to the treatment in adult patients with NS due to PGN.

Studies on the pharmacokinetics of piperacillin/tazobactam in renal replacement therapy in patients with chronic renal failure

“…Chronic renal failure patients may experience systemic damage as time goes on until terminal stage of renal failure which requires CRRT treatment [5][6][7][8][9][10]. The disease causes a series of adverse drug reactions.…”

Red Blood Cell Distribution Width is Associated with Glomerulonephritis in Diabetic Patients with Albuminuria

“…Results of our study also indicate that the predictive value of RDW mainly may be attributable to the inflammatory microenvironment in patients with diabetes who have GN. Another study has suggested that baseline RDW value is also a promising novel biomarker for predicting response to treatment in adult patients with nephrotic syndrome due to primary glomerulonephritides [ 31 ], which further underscores the clinical significance of RDW.…”

Ancho de distribución eritrocitaria como potencial biomarcador clínico en enfermedades cardiovasculares

“…Finalmente, si consideramos al RDW como un nuevo biomarcador y factor de riesgo, este debe cumplir una serie de requisitos para ser reconocido como tal dentro de los cuales podemos mencionar la capacidad de reflejar la magnitud del proceso medido, modificarse por efecto de las terapias, tener una metodología bien definida para su determinación y entregar información diagnóstica y pronóstica que pueda ser usada en la estratificación de riesgo de pacientes con ECV y adicionalmente, establecer una causalidad que sea independiente de otros factores confusores presentes 58 . Aunque existe resultados robustos en muchas de estas características anteriormente descritas, futuros estudios deben focalizarse, por ejemplo, en la evaluación del RDW y su potencial capacidad de modificarse por el uso de terapias, la cual ha sido estudiado preliminarmente 59 .…”